Spur Therapeutics

Gene therapies for chronic conditions.

man with pipette in lab, alognside microscope

Spur Therapeutics (formerly Freeline Therapeutics) is a clinical-stage biotechnology company focused on developing life-changing gene therapies for debilitating chronic conditions.

By optimising every component of its product candidates, Spur aims to unlock the true potential of gene therapy to realise outsized clinical results. Spur is advancing a breakthrough gene therapy candidate for Gaucher disease and a potential first-in-class gene therapy candidate for adrenomyeloneuropathy, as well as a research strategy to move gene therapy into more prevalent diseases, including forms of Parkinson’s, dementia, and cardiovascular disease.

Freeline spunout of UCL in 2015.

Dr. Rick Fagan

Director of BioPharm

Dr Fagan is a cell and molecular biologist by training, gaining his PhD at McGill University, Canada. This was followed by a postdoctorate at the Imperial Cancer Research Fund, London, and then the National Institute for Medical Research.

Richard left to join AstraZeneca as a team leader in the Department of Target Discovery, then worked for SanofiAventis as a senior team leader. In 2001 he left SanofiAventis and joined Impharmatica as Associate Director Target Discovery and worked very closely with the business development team.

In 2006 he joined UCL Ventures as Assistant Director BioPharm, becoming Director in 2007.